The development and clinical use of trastuzumab (Herceptin)

Endocrine-Related Cancer

Volumn 9, Issue 2, 2002, Pages 75-85

  Harries, Mark ^a   Smith, I ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GROWTH FACTOR RECEPTOR; LETROZOLE; MESSENGER RNA; METHOTREXATE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PLATINUM; PROTEIN TYROSINE KINASE; STEROID RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; THIOTEPA; TRASTUZUMAB; TYROSINE; UNINDEXED DRUG; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG BINDING; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HEART DISEASE; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NONHUMAN; NORTHERN BLOTTING; PREDICTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 0036323564     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0090075     Document Type: Article

References (60)

1. Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER2-overexpressing metastatic breast cancer (MBC)
2. Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?
3. Receptor blockade with monoclonal antibodies as anti-cancer therapy
4. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
5. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu-overexpressing human breast cancer xenografts
6. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
7. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer
8. Preoperative Herceptin and paclitaxel (Taxol) for HER2 overexpressing (HER2+) stage II/III breast cancer
9. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
10. Humanization of an anti-p185HER2 antibody for human cancer therapy
11. Myocyte survival pathways and cardiomyopathy: Implications for trastuzumab cardiotoxicity
12. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
13. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer
14. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
15. Radiolabeled antibody targeting of the HER-2/neu oncoprotein
16. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
17. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product
18. Analysis of HER1 and HER2 in the heart to clarify the cardiotoxicity of Herceptin
19. Pharmacokinetics (PK) and safety of Herceptin when administered every three weeks to women with metastatic breast cancer
20. Feasibility, pharmacology and antitumour activity of Herceptin (H) with doxorubicin and Taxol followed by weekly Taxol (AT&T) in women with HER2-positivie advanced breast cancer (ABC)
21. Prognostic importance of c-erbB-2 expression in breast cancer
22. The hallmarks of cancer
23. The humanized anti-HER2 antibody rhuMAb HER2 mediates antibody dependent cell-mediated cytotoxicity via FcgRIII
24. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
25. Primary therapy with Herceptin, Taxotere and cisplatin in locally advanced and inflammatory breast cancer
26. Multicentre phase II trial of weekly navelbine plus Herceptin in chemonaive patients with HER2 positive metastatic breast cancer
27. Amplification of a novel v-erbB-related gene in a human mammary carcinoma
28. HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer
29. A phase II trial of docetaxel and herceptin in metastatic breast cancer overexpressing HER-2
30. Phase II trial of weekly docetaxel (Taxotere) alone or in combination with trastuzumab (Herceptin) in patients with metastatic breast cancer
31. Improved survival benefit from Herceptin (trastuzumab) and chemotherapy in patients selected by fluorescence in situ hybridisation
32. The concordance between the clinical trials assay and flouresence in situ hybridisation in the Herceptin pivotal trials
33. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
34. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
35. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
36. Trastuzumab and chemotherapeutics: Drug interactions and synergies
37. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
38. HER2: A 'predictive factor' ready to use in the daily management of breast cancer patients?
39. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
40. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
41. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene
42. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
43. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
44. HER-2/neu (c-erb-B2) gene and protein in breast cancer
45. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth
46. The neu oncogene: An erb-B-related gene encoding a 185 000-Mr tumour antigen
47. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma
48. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
49. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts
50. Update on Taxotere/Platinum/Herceptin combinations
51. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
52. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
53. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
54. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
55. Effect of cardiac dysfunction on treatment outcome in the herceptin (trastuzumab) pivotal trial
56. A phase II trial of weekly docetaxel (D) and Herceptin (H) as first- or second-line treatment in HER-2 overexpressing metastatic breast cancer
57. Efficacy and safety of trastuzumab as single agent first-line treatment of HER2-overexpressing metastatic breast cancer
58. Reduced cardiotoxicity of liposome-encapsulated doxorubicin (TLC D-99) compared to free doxorubicin in first line-therapy of metastatic breast cancer in patients at increased risk for anthracycline-induced cardiac toxicity
59. Untangling the ErbB signalling network